UbiHealth

Biotechnology startup Altratech Ltd was founded with the vision to transform molecular diagnostics through nanotechnology. We have developed and patented a novel technology for molecular testing of viruses and pathogens in non-clinical environments. This all-synthetic novel assay can detect and quantify DNA, RNA, Antibody, and Antigen molecular targets, from blood or saliva samples, in 20 mins, without any need of centrifuges or pipettes. This will enable market-disrupting products that have the simplicity of a pregnancy test and the performance of a laboratory PCR test. All molecular diagnostic systems today require biological amplification, i.e., polymerase chain reaction (PCR), Loop-mediated polymerase amplification (LAMP), or similar. This takes time, and requires trained personnel, refrigeration for enzymes, and specialised equipment for heating/cooling and optical detection. It is because of these requirements that there is no solution on the market today for the non-clinical detection, monitoring, and management of viral infections such as HIV, Hepatitis, Influenza, Malaria, Meningitis, Shingles, Dengue Fever, HPV, EBV-related cancers, and many more. Our solution is a molecular detection process that eliminates the requirement for biological amplification and optical detection. We have invented and patented the key breakthrough of detecting and quantifying genetic material, viruses, and pathogens using almost instant ‘electronic signal amplification’, with semiconductor sensing and digital readout. The Value Proposition to our target customers, who will be the world’s leading diagnostic companies, is the ability to licence a novel patent protected product, with a wider range of market applications compared to their current diagnostic products. This will facilitate their entry into new markets and increase gross margins in existing markets. This innovation will impact the €48B Diagnostics industry.